Literature DB >> 13773354

Studies of the pharmacology of o,p'DDD in man.

R H MOY.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/pharmacology; DDT/related compounds

Mesh：

Substances：

Year:  1961        PMID： 13773354

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


× No keyword cloud information.
  11 in total

Review 1.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

2.  The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.

Authors:  Ségolène Hescot; Angelo Paci; Atmane Seck; Abdelhamid Slama; Say Viengchareun; Séverine Trabado; Sylvie Brailly-Tabard; Abir Al Ghuzlan; Jacques Young; Eric Baudin; Marc Lombès
Journal:  Horm Cancer       Date:  2014-07-16       Impact factor: 3.869

3.  o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.

Authors:  Y Touitou; A J Moolenaar; A Bogdan; A Auzéby; J P Luton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The effect of o,p'-DDD on the adrenal cortex in sheep.

Authors:  R Thun; P Wild; F Mettler; M Djafarian
Journal:  Experientia       Date:  1982-12-15

5.  O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.

Authors:  H von Slooten; A P van Seters; D Smeenk; A J Moolenaar
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.

Authors:  You Joung Heo; Jae Ho Yoo; Yun Soo Choe; Sang Hee Park; Seung Bok Lee; Hyun A Kim; Jung Yoon Choi; Young Ah Lee; Byung Chan Lim; Hee Won Chueh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2021-10-18

7.  Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.

Authors:  A J Moolenaar; H van Slooten; A P van Seters; D Smeenk
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.

Authors:  R Benecke; E Keller; B Vetter; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy.

Authors:  Takako Goto; Kenichi Miyako; Ryuichi Kuromaru; Kenji Ihara; Hiroyuki Torisu; Masafumi Sanefuji; Rie Nagamatsu; Toshiro Hara
Journal:  Clin Pediatr Endocrinol       Date:  2008-08-08

10.  Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?

Authors:  Yoann Cazaubon; Yohann Talineau; Catherine Feliu; Céline Konecki; Jennifer Russello; Olivier Mathieu; Zoubir Djerada
Journal:  Pharmaceutics       Date:  2019-10-31       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.